GL
VRTX icon

Graypoint LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Graypoint LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.26M Sell
2,839
-75
-3% -$34.6K 0.07% 182
2025
Q1 		$1.41M Buy
2,914
+12
+0.4% +$5.59K 0.09% 155
2024
Q4 		$1.17M Sell
2,902
-104
-3% -$48.2K 0.07% 177
2024
Q3 		$1.4M Buy
3,006
+101
+3% +$48.5K 0.09% 153
2024
Q2 		$1.36M Buy
2,905
+578
+25% +$251K 0.09% 146
2024
Q1 		$973K Buy
2,327
+88
+4% +$37.2K 0.07% 178
2023
Q4 		$911K Buy
2,239
+189
+9% +$69.8K 0.07% 178
2023
Q3 		$713K Buy
2,050
+339
+20% +$119K 0.07% 189
2023
Q2 		$602K Buy
1,711
+579
+51% +$195K 0.06% 189
2023
Q1 		$357K Buy
1,132
+312
+38% +$93.6K 0.04% 257
2022
Q4 		$237K Buy
820
+18
+2% +$5.49K 0.03% 302
2022
Q3 		$232K Buy
+802
New +$231K 0.03% 294

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Graypoint LLC's VRTX Position: Q2 2025 in Review

Graypoint LLC reduced its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q2 2025, selling an estimated $34.6K and leaving 2,839 shares worth $1.26M. The position accounts for 0.07% of the portfolio, ranked #182.

Graypoint LLC first reported a position in VRTX in Q3 2022 and has held it in 12 quarters since. The position peaked at $1.41M in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Graypoint LLC held 2,839 shares of Vertex Pharmaceuticals worth $1.26M as of Q2 2025.
  • Graypoint LLC sold 75 Vertex Pharmaceuticals shares in Q2 2025, an estimated $34.6K.
  • Vertex Pharmaceuticals made up 0.07% of Graypoint LLC's portfolio in Q2 2025, its #182 holding.
  • Graypoint LLC first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
  • Graypoint LLC's Vertex Pharmaceuticals position peaked at $1.41M in Q1 2025.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.